KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Operating Expenses (2016 - 2025)

Regeneron Pharmaceuticals has reported Other Operating Expenses over the past 17 years, most recently at $10.0 million for Q3 2025.

  • Quarterly results put Other Operating Expenses at $10.0 million for Q3 2025, up 225.0% from a year ago — trailing twelve months through Dec 2025 was $10.0 million (up 118.73% YoY), and the annual figure for FY2025 was $10.0 million, up 118.73%.
  • Other Operating Expenses for Q3 2025 was $10.0 million at Regeneron Pharmaceuticals, up from -$15.5 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for REGN hit a ceiling of $45.7 million in Q3 2022 and a floor of -$42.0 million in Q3 2021.
  • Median Other Operating Expenses over the past 5 years was $600000.0 (2023), compared with a mean of $5.5 million.
  • Biggest five-year swings in Other Operating Expenses: crashed 3200.0% in 2024 and later soared 225.0% in 2025.
  • Regeneron Pharmaceuticals' Other Operating Expenses stood at $15.8 million in 2021, then plummeted by 58.23% to $6.6 million in 2022, then crashed by 92.42% to $500000.0 in 2023, then crashed by 3200.0% to -$15.5 million in 2024, then skyrocketed by 164.52% to $10.0 million in 2025.
  • The last three reported values for Other Operating Expenses were $10.0 million (Q3 2025), -$15.5 million (Q4 2024), and -$8.0 million (Q3 2024) per Business Quant data.